Who is sponsoring NCT01942369?

NCT01942369 is sponsored by Ipsen.

What drugs are being tested in NCT01942369?

Interventions in NCT01942369: Triptorelin Acetate 3.75mg intramuscular injection.

What condition does NCT01942369 study?

NCT01942369 studies Deep Infiltrating Endometriosis (DIE).

Is NCT01942369 still recruiting?

NCT01942369 is currently completed. Last updated 6 December 2018.

Last reviewed 2018-12-06 · How we verify

NCT01942369: DIE-NIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months

Completed Last updated 6 December 2018

What this trial tests

trial testing Triptorelin Acetate 3.75mg intramuscular injection in Deep Infiltrating Endometriosis (DIE) in 402 participants. Completed in 13 July 2018.

Timeline

16 September 2013

Primary endpoint
13 July 2018

13 July 2018

Quick facts

Lead sponsor	Ipsen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	402
Start date	16 September 2013
Primary completion	13 July 2018
Estimated completion	13 July 2018
Sites	18 locations across China

Drugs / interventions tested

Triptorelin Acetate 3.75mg intramuscular injection — full drug profile →

Conditions studied

Deep Infiltrating Endometriosis (DIE) — all drugs for Deep Infiltrating Endometriosis (DIE) →

Sponsor

Ipsen — full company profile →

Who can join

18 and older, female only, with Deep Infiltrating Endometriosis (DIE). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to describe changes in the intensity of specific endometriosis symptoms from baseline pre-surgery to after surgery and subsequent continuous Diphereline (Triptorelin Acetate) treatment for up to 24 weeks.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The efficacy and safety of triptorelin-therapy following conservative surgery for deep infiltrating endometriosis: A multicenter, prospective, non-interventional study in China.
Zhu L, Guan Z, Huang Y, Hua K, et al · · 2022 · cited 5× · PMID 35119037 · DOI 10.1097/md.0000000000028766
Symptom control after different duration of triptorelin treatment following conservative surgery for deep infiltrating endometriosis: Post-hoc analysis of a multicentre, prospective, real-world study.
Sun W, Hua K, Hong L, Zhang J, et al · · 2021 · cited 1× · PMID 34397719 · DOI 10.1097/md.0000000000026753

Verify or expand the search:

Other recruiting trials for Deep Infiltrating Endometriosis (DIE)

Currently open trials in the same condition.

NCT06776536 — Evaluation of Rectal Infiltration Depth and Length in Bowel Involvement of Deep Infiltrative Endometriosis (DIE) Using I · NA · recruiting

Other Ipsen trials

Trials by the same sponsor.

NCT07387549 — A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis · Phase 3 · not yet recruiting
NCT07497724 — Retrospective Observational Study of Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-P · not yet recruiting
NCT07427797 — A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between · Phase 3 · recruiting
NCT07435428 — A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Line · Phase 3 · recruiting
NCT07441707 — A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01942369 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ipsen
Last refreshed: 6 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01942369.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing